Junji Yamauchi

Dr. Junji Yamauchi

Professor
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
YMYuki Miyamoto
Yuki Miyamoto
TTTomohiro Torii
Tomohiro Torii
Kenji TagoKenji Tago
Kenji Tago
ATAkito Tanoue
Akito Tanoue
STShou Takashima
Shou Takashima
Junji YamauchiJunji Yamauchi
Junji Yamauchi
BIG1 and its effector Arf1 are newly added to the list of signaling molecules controlling axonal myelination.

23 November 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
YMYuki Miyamoto
Yuki Miyamoto
TTTomohiro Torii
Tomohiro Torii
ATAkito Tanoue
Akito Tanoue
Junji YamauchiJunji Yamauchi
Junji Yamauchi
Oligodendrocytes differentiate to wrap their plasma membranes around axons, forming the myelin sheath. A neuronal cue is one of the regulator elements controlling this process. Here, we demonstrate that VCAM1, which plays a key role throughout the immune system, is also expressed in oligodendrocytes, where it regulates the initiation of myelination. VCAM1 knockout mice exhibit reduced myelin thickness. Decreased myelin thickness is also observed in mutant mice of α4 integrin, which is a neuronal VCAM1 ligand. Furthermore, CD69 is identified as one of the transcripts downregulated when VCAM1 is knocked down in oligodendrocytes. Knockdown of CD69 in mice indicates its role in myelination. Therefore, VCAM1 contributes not only to the initiation of myelination but also to its regulation through controlling the abundance of CD69, demonstrating that an intercellular molecule whose primary role is in the immune system can also play an unexpected role in the CNS.

3 October 2019 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
Kenji TagoKenji Tago
Kenji Tago
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
SOSatoshi Ohta
Satoshi Ohta
HKHirotoshi Kawata
Hirotoshi Kawata
HSHiroshi Saitoh
Hiroshi Saitoh
KYKen Yanagisawa
Ken Yanagisawa
It is well established that nuclear factor κB (NF‐κB) acts as one of the most important transcription factors for tumor initiation and progression, as it both protects cells from apoptotic/necrotic signals and accelerates angiogenesis and tumor metastasis, which is mediated via the expression of target genes. However, it has not yet been clarified how oncogenic signals accelerate the activation of NF‐κB. In the current study, we utilized untransformed NIH‐3T3 cells stably harboring a κB‐driven luciferase gene to show that an oncogenic mutant of Ras GTPase augmented TNFα‐induced NF‐κB activation. Notably, enforced expression of cyclin‐dependent kinase inhibitors, such as p27Kip1 and p21Cip1, effectively canceled the accelerated activation of NF‐κB, suggesting that oncogenic Ras‐induced cell cycle progression is essential for the hyperactivation of NF‐κB. Furthermore, we found that Ras (G12V) augmented the transcriptional activation of NF‐κB, and this activation required the p38 MAP kinase. We observed that a downstream kinase of p38 MAP kinase, MSK1, was activated by Ras (G12V) and catalyzed the phosphorylation of p65/RelA at Ser‐276, which is critical for its transcriptional activation. Significantly, phosphorylation of the p65/RelA subunit at Ser‐276 was elevated in patient samples of colorectal cancer harboring oncogenic mutations of the K‐Ras gene, and the expression levels of NF‐κB target genes were drastically enhanced in several cancer tissues. These observations strongly suggest that oncogenic signal‐induced acceleration of NF‐κB activation is caused by activation of the p38 MAP kinase–MSK1 signaling axis and by cell cycle progression in cancer cells.

24 November 2019
Verified
Book Chapter
Closed access
PDF file
TTTomohiro Torii
Tomohiro Torii
YMYuki Miyamoto
Yuki Miyamoto
Junji YamauchiJunji Yamauchi
Junji Yamauchi

31 May 2022 in Neurology International
Verified
Journal Article
Open access
PDF file
SNSatoshi Nishino
Satoshi Nishino
YFYoko Fujiki
Yoko Fujiki
TSTakanari Sato
Takanari Sato
YKYukino Kato
Yukino Kato
RSRemina Shirai
Remina Shirai
Junji YamauchiJunji Yamauchi
Junji Yamauchi
Oligodendrocytes (oligodendroglial cells) are glial cells that wrap neuronal axons with their differentiated plasma membranes called myelin membranes. In the pathogenesis of inflammatory cytokine-related oligodendroglial cell and myelin diseases such as multiple sclerosis (MS), typical inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) are thought to contribute to the degeneration and/or progression of the degeneration of oligodendroglial cells and, in turn, the degeneration of naked neuronal cells in the central nervous system (CNS) tissues. Despite the known involvement of these inflammatory cytokines in disease progression, it has remained unclear whether and how TNFα or IL-6 affects the oligodendroglial cells themselves or indirectly. Here we show that TNFα or IL-6 directly inhibits morphological differentiation in FBD-102b cells, which are differentiation models of oligodendroglial cells. Their phenotype changes were supported by the decreased expression levels of oligodendroglial cell differentiation and myelin marker proteins. In addition, TNFα or IL-6 decreased phosphorylation levels of Akt kinase, whose upregulation has been associated with promoting oligodendroglial cell differentiation. Hesperetin, a flavonoid mainly contained in citrus fruit, is known to have neuroprotective effects. Hesperetin might also be able to resolve pre-illness conditions, including the irregulated secretion of cytokines, through diet. Notably, the addition of hesperetin into cells recovered TNFα- or IL-6-induced inhibition of differentiation, as supported by increased levels of marker protein expression and phosphorylation of Akt kinase. These results suggest that TNFα or IL-6 itself contributes to the inhibitory effects on the morphological differentiation of oligodendroglial cells, possibly providing information not only on their underlying pathological effects but also on flavonoids with potential therapeutic effects at the molecular and cellular levels.

1 April 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YMYuki Miyamoto
Yuki Miyamoto
TTTomohiro Torii
Tomohiro Torii
ATAkito Tanoue
Akito Tanoue
KKKazuko Kawahara
Kazuko Kawahara
MAMiyuki Arai
Miyuki Arai
Junji YamauchiJunji Yamauchi
Junji Yamauchi